Quantum BioPharma

08/31/2026

Quantum BioPharma (NASDAQ: QNTM). The company is advancing Lucid-21-302, a novel oral therapeutic candidate targeting protein arginine deiminase, or PAD, biology in multiple sclerosis. The program offers a differentiated approach centered on neuroprotection and myelin preservation, with several important development milestones ahead.

Please reach out directly or at [email protected] to request the full initiation report. More to come.

08/18/2026

3rd Party Article Mentioning Quantum BioPharma & Lucid-MS
NeurologyLive


https://neurologylive.com/view/fda-clears-phase-2-trial-demyelinating-agent-lucid-ms-progressive-multiple-sclerosis

$QNTM

08/10/2026

Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis

Major Regulatory Milestone Positions Company to Initiate Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Patented First-in-Class Neuroprotective Therapy Targeting Demyelination

Lucid-MS Advances Novel Disease-Modifying Approach Targeting Multi-Billion Dollar Progressive MS Market with Significant Unmet Medical Need Worldwide

https://www.globenewswire.com/news-release/2026/08/10/3341697/0/en/quantum-biopharma-receives-united-states-fda-clearance-to-proceed-with-lucid-ms-phase-2-trial-in-progressive-multiple-sclerosis.html

07/24/2026

Most MS therapies modulate immunity. Quantum BioPharma’s investigational Lucid-MS is designed to address citrullination and myelin integrity through a differentiated, non-immunosuppressive approach.

Learn more: https://www.quantumbiopharma.com/lucid-ms

$QNTM

06/19/2026

Reframing MS starts with looking beyond the traditional autoimmune lens.

Quantum BioPharma’s Lucid-MS program is exploring neurodegenerative biology, myelin-related mechanisms, and a non-immunomodulatory research approach in multiple sclerosis.

Visit www.quantumbiopharma.com for more info.

06/08/2026

Multiple sclerosis remains a major unmet medical challenge.

Quantum BioPharma's investigational drug candidate, Lucid-MS, is a new chemical entity (NCE) being developed to target citrullination-driven demyelination through a non-immunosuppressive and non-immunomodulatory approach.

Research suggests excessive citrullination may alter myelin proteins and contribute to myelin damage, impacting nerve signaling.

✅ Novel mechanism under investigation
✅ Focused on demyelination biology
✅ Addressing an important unmet need in MS research

Lucid-MS is investigational and not approved by the FDA or Health Canada.

$QNTM

www.quantumbiopharma.com

06/05/2026

Quantum BioPharma continues advancing its Lucid-MS program with a focus on demyelination and neuroprotective pathways in Multiple Sclerosis.

Phase 1 complete. IND submitted for Phase 2 trial design.

Lucid-MS is investigational and not approved by FDA or Health Canada.

Sign up for email alerts : https://quantumbiopharma.com/email-alerts


$QNTM

06/02/2026

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is featured in the latest episode of The BioMedWire Podcast, with Anthony Durkacz, Co-Founder and Executive Co-Chair, discussing the company’s Lucid-MS development program, unbuzzd™ commercial strategy, and key milestones ahead for 2026.

The conversation highlights Quantum BioPharma’s focus on multiple sclerosis research, demyelination, neurodegenerative disease, and the broader strategy behind its biotech and commercial asset portfolio.

Watch the full episode here:
https://www.youtube.com/watch?v=clA0PZNfY1A

Lucid-MS is an investigational drug candidate. It is not approved by the FDA, Health Canada, or any other regulatory authority. This post is for informational purposes only and does not constitute medical advice, investment advice, or a recommendation to buy or sell securities.

Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPh...

06/01/2026

Most approved MS therapies are designed to modulate or suppress the immune system.

But the immune system may not be the whole story.

For decades, MS treatment has largely focused on reducing immune-driven attacks. Quantum BioPharma
$QNTM
is exploring a different scientific question: whether MS also involves neurodegenerative mechanisms tied directly to myelin damage.

This is the demyelination pathway.

Lucid-MS, also known as LUCID-21-302, is being developed as a non-immunomodulatory investigational new chemical entity designed to target PAD2 an enzyme involved in abnormal myelin protein citrullination, a process believed to increase myelin vulnerability in MS.

In preclinical animal models, Lucid-MS demonstrated signals supporting further research into this mechanism.

Rather than targeting the immune system, Lucid-MS is focused on the biology of demyelination itself.

A different mechanism. A different pathway. A different approach to MS research. No Drugs currently on the market that are approved do what Lucid-MS is designed to do.

Lucid-MS is a Investigational drug candidate. Not approved by the FDA or Health Canada. Currently in clinical development.

05/26/2026

Quantum BioPharma recently announced a key midpoint milestone in its separate collaborative imaging study with Massachusetts General Hospital, centered on [¹⁸F]3F4AP PET imaging to help assess demyelination in Multiple Sclerosis.

While this study is separate from Lucid-MS trials, we believe this type of imaging research could one day help support the broader scientific understanding of how demyelination is measured and tracked in MS research.

Lucid-MS has completed prior Phase 1 clinical development, and Quantum BioPharma has submitted an IND application to the FDA for a Phase 2 clinical trial.

As Quantum BioPharma’s lead investigational candidate, Lucid-MS was designed to target neurodegenerative pathways linked to the citrullination cascade, representing a differentiated scientific approach from traditional immunomodulatory therapies.

Learn more in our May 18, 2026 news release.
https://www.globenewswire.com/news-release/2026/05/18/3296317/0/en/quantum-biopharma-reaches-key-midpoint-milestone-in-groundbreaking-imaging-study-with-massachusetts-general-hospital.html

$QNTM